MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the Health Care industry. TD Cowen | Boston, MA | March 3-5, 2025Presentation: Tuesday, March 4, 2025 at 11:10 AM ETWebcast: Click here to access Institutional i

Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are pleased today to report solid fourth quarter and full year 2024 results. With fourth quarter net sales

MARIETTA, Ga., Feb. 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2024 after the market close on Wednesday, February 26, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13751444 A replay of the webcast will be available for approximately 30 days on

MARIETTA, Ga., Dec. 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has filed a lawsuit against Surgenex, LLC in the United States District Court for the District of Arizona. The complaint asserts that several of Surgenex's placental allograft products infringe the Company's patents and seeks permanent injunctive relief and monetary damages. This matter represents the second lawsuit by MIMEDX against Surgenex, following ongoing litigation filed earlier this year alleging a corporate raiding scheme on the Company's commercial organization and unfair competitive practices. Joseph H. Capper, MIMEDX Chief Executive Officer, com

MARIETTA, Ga., Dec. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Mizuho Health Care ConferenceWednesday, December 11, 20241:1 sessions | New York, NY Northland Growth ConferenceThursday, December 12, 20241:1 sessions | Virtual Stifel MedTech West Coast Bus TourThursday, December 12, 20241:1 sessions | Palo Alto, CA Investors interested in meeting with senior management at these events may contact their respective Mizuho, Northland Capital or Stifel representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans

Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today provided the following update on the Local Coverage Determinations ("LCDs") regarding "Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers."   These new LCDs were originally proposed in April 2024, with a comment period that concluded in June 2024. The LCDs are now set to become effective on February 12, 2025. As a result of industry feedback, t

MARIETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Stifel Healthcare Conference 2024Webcast (9:45 AM ET): Click here to accessMonday, November 18, 2024New York, NY 15th Annual Craig-Hallum Alpha Select ConferenceTuesday, November 19, 2024New York, NY Investors interested in meeting with senior management at these events may contact their respective Stifel or Craig-Hallum representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic

Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18 Million, or 22% of Net SalesRaises 2024 Net Sales Growth Expectations to the High Single-DigitsManagement to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the third quarter 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid third quarter 2024 results include total net sales growth of 3% year-

MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13748866 A replay of the webcast will be available for approximately 30 days on the Company's

Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research   MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall is the largest gathering of advanced wound care industry and healthcare professionals and serves as an educational forum to connect with this global community. "Our research and clinical teams have continued to extend our leadership in expanding the understan

Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

Mizuho initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $7.00

HC Wainwright & Co. reiterated coverage of MiMedx Group with a rating of Buy and set a new price target of $8.50 from $20.00 previously

Northland Capital initiated coverage of MiMedx Group with a rating of Outperform and set a new price target of $23.00

H.C. Wainwright initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $20.00

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

10-K - MIMEDX GROUP, INC. (0001376339) (Filer)

8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)

144 - MIMEDX GROUP, INC. (0001376339) (Subject)

8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

MARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has appointed Doug Rice as the Company's Chief Financial Officer, effective today. Pete Carlson, who has served in that role since March 2020, has resigned as Chief Financial Officer, also effective today. Mr. Rice joins MIMEDX after nearly a decade as the CFO of Orthofix Medical, a leading global spine and orthopedics company, following the company's recent merger with SeaSpine. Prior to Orthofix, Mr. Rice was also CFO at Vision Source, held several finance leadership roles, including at McAfee and Concentra, and started his career at PricewaterhouseCooper

MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company's manufacturing, supply chain, procurement, quality, and regulatory functions. Ms. Whitlow joins MIMEDX from Catalent, where she most recently served as President, Clinical Supply Services. "We are happy to begin 2023 with the addition of Ricci Whitlow to the MIMEDX leadership team," stated Todd Newton, MIM

Experienced Healthcare-focused Financial and Communications Leader to Strengthen and Expand Relationships with Investment Community MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced the appointment of Matt Notarianni as Head of Investor Relations (IR), effective immediately. Mr. Notarianni joins MIMEDX with over 15 years of healthcare-focused Wall Street and IR experience, most recently serving as head of IR for Cerus Corporation. "I am delighted to welcome Matt to MIMEDX," stated K. Todd Newton, MIMEDX interim Chief Executive Officer. "The breadth of Matt's experi

K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w

No Shareholder Action Required at This Time MARIETTA, Ga., April 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MiMedx" or the "Company"), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Point Capital Management ("Prescience Point") submitted a notice of nomination of Eiad Asbahi, Alfred G. Merriweather, Charlotte E. Sibley and William F. Spengler candidates to stand for election to MiMedx's Board of Directors at the Company's 2021 Annual Meeting of Shareholders, scheduled for May 27, 2021. MiMedx issued the following statement: "The MiMedx Board is made up of nine talented, experienced and highly eng

Noted biopharmaceutical thought leader adds academic, research and industry expertise MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced the appointment of Phyllis Gardner, M.D. to its Board of Directors. Regarded for her contributions and accomplishments across academia, biotechnology, and the healthcare industry, Dr. Gardner, a professor of medicine at the Stanford University School of Medicine and distinguished business leader, brings to MiMedx more than 35 years of experience, marked by numerous national awards and honors.

Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are pleased today to report solid fourth quarter and full year 2024 results. With fourth quarter net sales

MARIETTA, Ga., Feb. 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2024 after the market close on Wednesday, February 26, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13751444 A replay of the webcast will be available for approximately 30 days on

Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18 Million, or 22% of Net SalesRaises 2024 Net Sales Growth Expectations to the High Single-DigitsManagement to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the third quarter 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid third quarter 2024 results include total net sales growth of 3% year-

MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13748866 A replay of the webcast will be available for approximately 30 days on the Company's

Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024, at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2024. Recent Operating and Financial Highlights: Second quarter 2024 net sales of $87 million, reflecting 7% growth over the prior year period.GAAP net income from continuing operat

MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 31, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13747365 A replay of the webcast will be available for approximately 30 days on the Company's website

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024, at 4:30 PM ET MARIETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2024. Recent Operating and Financial Highlights: First quarter 2024 net sales of $85 million, reflecting 18% growth over the prior year period.GAAP net income from continuing operations and net margin for the first quarter 2024 of $9 million an

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13745475 A replay of the webcast will be available for approximately 30 days on the Company's website

Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has issued a determination letter in connection with the RFD process related to AXIOFILL, a human-derived particulate wound dressing. In the letter, FDA reaffirmed its position that AXIO

Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $21 million, or 24% of Net Sales Management to Host Conference Call Today, February 28, 2024, at 4:30 PM ET MARIETTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2023. Recent Operating and Financial Highlights: Fourth quarter and full year 2023 net sales of $87 million and $321 million, reflecting 17% and 20% year-over-year growth,

SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13D/A - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13D/A - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13D - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)